Chapter 46: Immunopharmacology, Biologicals, and Gene Therapy

Immunopharmacology, Biologicals, and Gene Therapy academic overview explores the cutting-edge fields of immunopharmacology, biologicals, and gene therapy, detailing how molecular precision is reshaping modern medicine. It begins with the manufacturing and nomenclature of monoclonal antibodies, explaining how laboratory-engineered hybridoma cells produce targeted proteins that block specific cell surface receptors or cytokines. These agents are categorized by their application in oncology—such as inhibiting growth factor pathways like EGFR and HER2, or utilizing immune checkpoint inhibitors to restore the body’s natural defense against tumors—and their use in chronic conditions like asthma, migraine, and rheumatoid arthritis. The discussion extends to antibody-drug conjugates, which combine the specificity of antibodies with the potency of chemotherapy. The chapter also provides a comprehensive look at vaccinology, comparing traditional live-attenuated and inactivated methods with contemporary recombinant and mRNA platforms used to generate immunity against viral and bacterial pathogens across the lifespan. For the management of organ transplantation, it examines the pharmacological mechanisms of immunosuppressants, including calcineurin inhibitors, mTOR antagonists, and corticosteroids, which prevent allograft rejection by modulating T-cell activation and cytokine production. Furthermore, the text introduces groundbreaking gene therapy techniques, such as antisense oligonucleotides that target mRNA to prevent disease-linked protein synthesis and viral vector-based gene modifications designed to correct genetic mutations or engineer autologous T-cells for refractory hematologic malignancies.